Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2878 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 04 Nov 2026, 03:15 UTC
2878
Studies in scope
industry-sponsored, all four open statuses
1384
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 73 Glasgow 15 Oxford 13 Sheffield 12 Cambridge 12
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca139 Merck Sharp & Dohme LLC98 Hoffmann-La Roche83 Novartis Pharmaceuticals73 Janssen Research & Development, LLC71 Clear sponsor filter
Site city
London73 Glasgow15 Oxford13 Sheffield12 Cambridge12
All 75 cities
Target enrolment
to

Trials with a site in London

73 of 2878 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
180
London
2026-09-18
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Cambridge, London
2026-06-03
Recruiting
Novartis Pharmaceuticals
Phase 1
24
London
2026-05-19
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Dorchester, London, Preston, Harrow, Rochdale, Portadown, Taunton, Chertsey
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
London
2026-01-13
Recruiting
Novartis Pharmaceuticals
Observational
3,000
London
2025-12-15
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Bristol, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Brighton, Newcastle upon Tyne, Liverpool, London
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Sutton, London
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Liverpool, London
2025-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
97
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Oxford, Sutton, Windsor, London
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Glasgow, London
2025-05-30
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Dudley, Liverpool, London
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Chichester, London, Manchester, Tyne and Wear
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 1/2
15
Sheffield, London
2025-04-22
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
London
2025-04-03
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Leeds, Bristol, Cardiff, London, Southampton
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Cambridge, Glasgow, London, Manchester
2025-03-13
Active, closed
Novartis Pharmaceuticals
Phase 3
180
London
2025-02-07
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sheffield, London
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 3
60
West Midlands, London
2024-12-09
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Sheffield, Cambridge, London
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Sheffield, Farnborough, London, Stoke-on-Trent
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Bristol, London
2024-10-09
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Sheffield, London
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
London, Sheffield
2024-08-14
Recruiting
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356Hematologic Malignancy, Solid Tumor, Advanced Malignancies
DrugPelabresib
Novartis Pharmaceuticals
Phase 3
50
Cardiff, Glasgow, London
2024-08-13
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Inverness, Swinton, Birmingham, London, Southampton
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 1
31
Sutton, London
2024-07-29
Recruiting
Novartis Pharmaceuticals
Phase 3
450
Bristol, Guildford, Coventry, London
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Reading, Portadown, Edinburgh, Leicester, Liverpool, London, Londonderry, Manchester
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Glasgow, Newcastle upon Tyne, London
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
232
London
2023-11-24
Recruiting
Novartis Pharmaceuticals
Phase 3
106
Belfast, Cardiff, London, Manchester, Salford
2023-10-02
Active, closed
Novartis Pharmaceuticals
Phase 2
144
Birmingham, Cardiff, London, Manchester
2023-08-25
Active, closed
Novartis Pharmaceuticals
Phase 2
41
Glasgow, London
2023-08-16
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Bristol, Brighton, Salford, Leicester, London, Nottingham
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
123
Oxford, London
2023-06-27
Active, closed
Novartis Pharmaceuticals
Phase 1
71
Cardiff, London, Manchester
2023-05-08
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Birmingham, London, Nottingham
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
London, Oxford
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Birmingham, Leeds, London
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
20
London, Newcastle upon Tyne
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Glasgow, Gloucester, London, Newport
2022-11-21
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
London, Oxford
2022-08-30
Recruiting
Novartis Pharmaceuticals
Phase 2
42
London, Stoke-on-Trent
2022-08-29
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Bradford, London
2022-07-14
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
London, Nottingham, Oxford
2021-10-06
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Newcastle upon Tyne, Cambridge, Leicester, London, Salford
2021-09-20
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Glasgow, Newcastle upon Tyne, London
2021-07-28
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Leeds, London
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Guildford, Sutton, Coventry, London, Middlesbrough
2021-06-15
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Sutton, Belfast, Cambridge, Glasgow, London, Middlesbrough
2021-06-09
Active, closed
Novartis Pharmaceuticals
Phase 2
236
West Midlands, London, Manchester
2021-04-19
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Sheffield, London
2021-03-15
Active, closed
Novartis Pharmaceuticals
Phase 2
17
London
2020-12-18
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Bristol, Hertford, Leicester, London, Salford
2020-12-11
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Sutton, Liverpool, London
2019-11-04
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Newcastle upon Tyne, Cardiff, London
2019-10-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
Novartis Pharmaceuticals
Phase 3
253
Sheffield, Cambridge, London
2019-07-26
Active, closed
Novartis Pharmaceuticals
Phase 2
121
London
2019-06-24
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Birmingham, Buckinghamshire, Cambridge, Liverpool, London, Sheffield
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Birmingham, London
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 3
240
West Midlands, Edinburgh, London
2013-07-26
Rows per page Showing 1–73 of 73
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 4 November 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,878 studies in total at the last sync on 04 Nov 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 73 of those studies with a site in London that also match the filters currently applied.

How many clinical trials are recruiting in London?

31 of the 73 studies on this page are recruiting new participants as of the 04 Nov 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 42 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (London), 73 studies
PhaseStudiesRecruitingShare
Phase 3381552.1%
Phase 219726%
Phase 1/2759.6%
Phase 1415.5%
Phase 4314.1%
Observational111.4%
Phase 2/3111.4%

Most active sponsors

Lead sponsors with the most studies (London)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals7331
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.